PHASE II STUDY OF COMBINATION CHEMOTHERAPY WITH BIWEEKLY CETUXIMAB AND IRINOTECAN FOR WILD-TYPE KRAS METASTATIC COLORECTAL CANCER REFRACTORY TO IRINOTECAN, OXALIPLATIN, AND FLUOROPYRIMIDINES

被引：0
|
作者：
Yuki, S. [1 ]
Shitara, K. [2 ]
Yoshida, M. [3 ]
Takahari, D. [2 ]
Utsunomiya, S. [4 ]
Yokota, T. [2 ]
Sato, Y. [2 ]
Tajika, M. [2 ]
Muro, K. [2 ]
机构：
[1] Hokkaido Univ Hosp, Sapporo, Hokkaido 060, Japan
[2] Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan
[3] Osaka Med Coll, Takatsuki, Osaka 569, Japan
[4] Nagoya Kyouritsu Hosp, Nagoya, Aichi, Japan
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：216 / 216
页数：1
相关论文
共 50 条
  • [21] Biweekly cetuximab and irinotecan for the treatment of refractory metastatic colorectal cancer
    Martín-Martorell, Paloma
    Rodriguez-Braun, Edith
    Perez-Fidalgo, Alejandro
    Chirivella, Isabel
    Insa, Amelia
    Cervantes, Andrés
    ANNALS OF ONCOLOGY, 2007, 18 : 168 - 168
  • [22] Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status
    Myoung Joo Kang
    Yong Sang Hong
    Kyu-pyo Kim
    Sun Young Kim
    Ji Yeon Baek
    Min-Hee Ryu
    Jae-Lyun Lee
    Heung Moon Chang
    Mi-Jung Kim
    Hee Jin Chang
    Yoon-Koo Kang
    Tae Won Kim
    Investigational New Drugs, 2012, 30 : 1607 - 1613
  • [23] Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status
    Kang, Myoung Joo
    Hong, Yong Sang
    Kim, Kyu-pyo
    Kim, Sun Young
    Baek, Ji Yeon
    Ryu, Min-Hee
    Lee, Jae-Lyun
    Chang, Heung Moon
    Kim, Mi-Jung
    Chang, Hee Jin
    Kang, Yoon-Koo
    Kim, Tae Won
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) : 1607 - 1613
  • [24] Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer
    Osumi, Hiroki
    Shinozaki, Eiji
    Mashima, Tetsuo
    Wakatsuki, Takeru
    Suenaga, Mitsukuni
    Ichimura, Takashi
    Ogura, Mariko
    Ota, Yumiko
    Nakayama, Izuma
    Takahari, Daisuke
    Chin, Keisho
    Miki, Yoshio
    Yamaguchi, Kensei
    CANCER SCIENCE, 2018, 109 (08) : 2567 - 2575
  • [25] Cetuximab and irinotecan in patients with colorectal cancer refractory to oxaliplatin and irinotecan
    Gonzalez-Baron, M.
    Blanco, M.
    Feliu, J.
    Gomez, C.
    Casado, E.
    Castro, J.
    Belda-Iniesta, C.
    Garrido, M.
    Aguayo, C.
    Campos, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [26] Phase II study of combination therapy with S-1 and cetuximab in patients with KRAS wild-type unresectable colorectal cancer who had previously received irinotecan, oxaliplatin, and fluoropyrimidines (KSCC0901).
    Kobayashi, Kazuma
    Emi, Yasunori
    Kakeji, Yoshihiro
    Takahashi, Takao
    Oki, Eiji
    Akagi, Yoshito
    Tsuji, Akihito
    Kodera, Yasuhiro
    Yoshida, Kazuhiro
    Baba, Hideo
    Shimada, Mitsuo
    Ogata, Yutaka
    Shimokawa, Mototsugu
    Tokunaga, Shoji
    Natsugoe, Shoji
    Maehara, Yoshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Cetuximab/Irinotecan-Chemotherapy in KRAS Wild-type Pretreated Metastatic Colorectal Cancer: A Pooled Analysis and Review of Literature
    Barni, Sandro
    Ghilardi, Mara
    Borgonovo, Karen
    Cabiddu, Mary
    Zaniboni, Alberto
    Petrelli, Fausto
    REVIEWS ON RECENT CLINICAL TRIALS, 2013, 8 (02) : 101 - 109
  • [28] PHASE II STUDY OF COMBINATION THERAPY WITH S-1 AND CETUXIMAB IN PATIENTS WITH KRAS WILD-TYPE UNRESECTABLE COLORECTAL CANCER, WHO HAD PREVIOUSLY RECEIVED IRINOTECAN, OXALIPLATIN, AND FLUOROPYRIMIDINES (KSCC0901)
    Kitazono, M.
    Kobayashi, K.
    Emi, Y.
    Kakechi, Y.
    Takahashi, T.
    Akagi, Y.
    Tuji, A.
    Yoshida, K.
    Baba, H.
    Ogata, H.
    Shimokawa, M.
    Natsugoe, S.
    Maehara, Y.
    ANNALS OF ONCOLOGY, 2012, 23 : 122 - 122
  • [29] Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study)
    Takahashi, Takao
    Emi, Yasunori
    Oki, Eiji
    Kobayashi, Kazuma
    Tsuji, Akihito
    Shimokawa, Mototsugu
    Tanaka, Takaho
    Akagi, Yoshito
    Ogata, Yutaka
    Baba, Hideo
    Yoshida, Kazuhiro
    Natsugoe, Shoji
    Maehara, Yoshihiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (03) : 585 - 593
  • [30] Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study)
    Takao Takahashi
    Yasunori Emi
    Eiji Oki
    Kazuma Kobayashi
    Akihito Tsuji
    Mototsugu Shimokawa
    Takaho Tanaka
    Yoshito Akagi
    Yutaka Ogata
    Hideo Baba
    Kazuhiro Yoshida
    Shoji Natsugoe
    Yoshihiko Maehara
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 585 - 593
12345